2024
Stress-induced mucin 13 reductions drive intestinal microbiome shifts and despair behaviors
Rivet-Noor C, Merchak A, Render C, Gay N, Beiter R, Brown R, Keeler A, Moreau G, Li S, Olgun D, Steigmeyer A, Ofer R, Phan T, Vemuri K, Chen L, Mahoney K, Shin J, Malaker S, Deppmann C, Verzi M, Gaultier A. Stress-induced mucin 13 reductions drive intestinal microbiome shifts and despair behaviors. Brain Behavior And Immunity 2024, 119: 665-680. PMID: 38579936, PMCID: PMC11187485, DOI: 10.1016/j.bbi.2024.03.028.Peer-Reviewed Original ResearchMicrobiome shiftsDespair behaviorTranscription factor familyChronic stressRegulation of mucinsState of dysbiosisMicrobiome composition changesAssociated with disease pathologyDepressive-like symptomsModel of chronic stressLimited treatment optionsContext of stressHuman microbiomeMicrobiome compositionPsychological stress exposureMicrobial compositionFactor familyMicrobial dysbiosisMicrobial changesMicrobiome dysbiosisMicrobiomeTreatment optionsUpstream mediatorDepressive symptomsStress exposure
2020
Targeted glycan degradation potentiates the anticancer immune response in vivo
Gray MA, Stanczak MA, Mantuano NR, Xiao H, Pijnenborg JFA, Malaker SA, Miller CL, Weidenbacher PA, Tanzo JT, Ahn G, Woods EC, Läubli H, Bertozzi CR. Targeted glycan degradation potentiates the anticancer immune response in vivo. Nature Chemical Biology 2020, 16: 1376-1384. PMID: 32807964, PMCID: PMC7727925, DOI: 10.1038/s41589-020-0622-x.Peer-Reviewed Original ResearchMeSH KeywordsAllograftsAnimalsAntibodies, MonoclonalB7-H1 AntigenCell Line, TumorHumansHydrolysisImmunoconjugatesImmunotherapyKiller Cells, NaturalMelanoma, ExperimentalMiceMice, Inbred C57BLMice, KnockoutModels, MolecularMolecular Targeted TherapyNeuraminidasePolysaccharidesProgrammed Cell Death 1 ReceptorProtein BindingProtein Interaction Domains and MotifsProtein Structure, SecondaryReceptor, ErbB-2Sialic Acid Binding Immunoglobulin-like LectinsSurvival AnalysisT-LymphocytesConceptsImmune checkpoint inhibitor therapyTumor-infiltrating myeloid cellsCheckpoint inhibitor therapyImmune cell infiltrationPowerful treatment optionAnticancer immune responseSurvival of miceSyngeneic breast cancer modelImmune cell activationBreast cancer modelBreast cancer cellsCheckpoint therapyMost patientsInhibitor therapyPD-1Checkpoint receptorsImmune suppressionTreatment optionsCell infiltrationImmune responseMyeloid cellsCancer modelCell activationCertain cancersCancer types